Matches in Wikidata for { <http://www.wikidata.org/entity/Q91535056> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q91535056 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q91535056 description "scientific article published on 03 April 2020" @default.
- Q91535056 description "wetenschappelijk artikel" @default.
- Q91535056 description "наукова стаття, опублікована 3 квітня 2020" @default.
- Q91535056 description "գիտական հոդված հրատարակված 2020 թվականի ապրիլի 3-ին" @default.
- Q91535056 name "A Phase II Trial Evaluating The Efficacy of High-Dose Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma" @default.
- Q91535056 name "A Phase II Trial Evaluating The Efficacy of High-Dose Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma" @default.
- Q91535056 type Item @default.
- Q91535056 label "A Phase II Trial Evaluating The Efficacy of High-Dose Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma" @default.
- Q91535056 label "A Phase II Trial Evaluating The Efficacy of High-Dose Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma" @default.
- Q91535056 prefLabel "A Phase II Trial Evaluating The Efficacy of High-Dose Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma" @default.
- Q91535056 prefLabel "A Phase II Trial Evaluating The Efficacy of High-Dose Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma" @default.
- Q91535056 P1433 Q91535056-3EE935DE-03D1-4CF2-A7EC-882FAE869C1F @default.
- Q91535056 P1476 Q91535056-96CED39D-4B9E-4E5C-A581-B638D40513E2 @default.
- Q91535056 P2093 Q91535056-0B48DEB5-61DF-4484-BBAE-ED3464AD2368 @default.
- Q91535056 P2093 Q91535056-30201F29-6DF6-4289-B9FD-2095B0A732F3 @default.
- Q91535056 P2093 Q91535056-3F23563C-C374-4C93-BB74-056740AFA2BA @default.
- Q91535056 P2093 Q91535056-3F9D915F-9D08-423A-A926-C92A97A9640C @default.
- Q91535056 P2093 Q91535056-4727C301-D825-475A-A07C-496CEBCF772A @default.
- Q91535056 P2093 Q91535056-4C67D05C-1D03-46E1-9189-58F4E5A7044D @default.
- Q91535056 P2093 Q91535056-5127A28F-8DF4-4E0D-AA05-8794D93E53D5 @default.
- Q91535056 P2093 Q91535056-79DDB9D8-08D4-45B5-AA96-3A90E9D9D232 @default.
- Q91535056 P2093 Q91535056-B1816862-8E3E-4082-AF50-7AAB1A0CAF43 @default.
- Q91535056 P2093 Q91535056-C3D50077-6802-4C7C-9605-27E3B3A32F46 @default.
- Q91535056 P2093 Q91535056-E533CCE8-1F79-47F3-A527-C81F3722613C @default.
- Q91535056 P31 Q91535056-95FBE33C-5143-4099-B561-28CAB343170B @default.
- Q91535056 P356 Q91535056-57C3CA16-1AA5-450F-B223-EEA564F6299B @default.
- Q91535056 P50 Q91535056-5FA0C27B-2228-41E8-96D5-8B960C4EDCFA @default.
- Q91535056 P50 Q91535056-B0C79413-2D9D-40A8-9DA1-3FCD434E1A3A @default.
- Q91535056 P577 Q91535056-D8EF729B-BA69-4E89-A504-A15028A549A0 @default.
- Q91535056 P698 Q91535056-17070F80-B0F2-4769-B149-08D56A2CEDA7 @default.
- Q91535056 P921 Q91535056-57A759C6-2388-4FB6-BEC1-D5FAAD014AA0 @default.
- Q91535056 P921 Q91535056-8AA8F274-D8E2-47B2-B613-54ABB71E34CD @default.
- Q91535056 P921 Q91535056-BFD8C857-2E0D-4013-8408-60B9529BF5FA @default.
- Q91535056 P356 AJH.25818 @default.
- Q91535056 P698 32243637 @default.
- Q91535056 P1433 Q4744246 @default.
- Q91535056 P1476 "A Phase II Trial Evaluating The Efficacy of High-Dose Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma" @default.
- Q91535056 P2093 "Ajay K Gopal" @default.
- Q91535056 P2093 "Damian J Green" @default.
- Q91535056 P2093 "Darrell R Fisher" @default.
- Q91535056 P2093 "John M Pagel" @default.
- Q91535056 P2093 "Joseph G Rajendran" @default.
- Q91535056 P2093 "Leona A Holmberg" @default.
- Q91535056 P2093 "Oliver W Press" @default.
- Q91535056 P2093 "Paul S Martin" @default.
- Q91535056 P2093 "Philip A Stevenson" @default.
- Q91535056 P2093 "Ryan D Cassaday" @default.
- Q91535056 P2093 "Theodore A Gooley" @default.
- Q91535056 P31 Q13442814 @default.
- Q91535056 P356 "10.1002/AJH.25818" @default.
- Q91535056 P50 Q75025725 @default.
- Q91535056 P50 Q89143221 @default.
- Q91535056 P577 "2020-04-03T00:00:00Z" @default.
- Q91535056 P698 "32243637" @default.
- Q91535056 P921 Q3995913 @default.
- Q91535056 P921 Q418817 @default.
- Q91535056 P921 Q42824440 @default.